Neuroendocrine tumor diagnosis and management: 68 Ga-DOTATATE PET/CT

Yasemin Sanli, Ishan Garg, Asha Kandathil, Ayse Tuba Kendi, Maria J. Baladron Zanetti, Serkan Kuyumcu, Rathan M. Subramaniam

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

OBJECTIVE. The purpose of this article is to provide a review of the use of 68 Ga tet-raazacyclododecanetetraacetic acid–DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a functional imaging modality for assessment of well-differentiated neuroendocrine tumors (NETs). It has become the preferred imaging modality for initial diagnosis, selection of patients for peptide receptor radionuclide therapy, and localization of unknown primary tumors. The National Comprehensive Cancer Network guideline has added 68 Ga-DOTATATE PET/CT as an appropriate test in the management of NETs. CONCLUSION. In combination with FDG PET/CT, 68 Ga-DOTATATE PET/CT can noninvasively assess tumor heterogeneity, especially in G2 and G3 NETs, for personalized management of patients.

Original languageEnglish (US)
Pages (from-to)267-277
Number of pages11
JournalAmerican Journal of Roentgenology
Volume211
Issue number2
DOIs
StatePublished - Aug 1 2018

Keywords

  • Ga-DOTATATE
  • Neuroendocrine tumor
  • PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Neuroendocrine tumor diagnosis and management: <sup>68</sup> Ga-DOTATATE PET/CT'. Together they form a unique fingerprint.

Cite this